Loading...

CRSP CRISPR THERAPEUTICS AG Other Situations 8-K Filing

CRSP

CRSP

CRISPR THERAPEUTICS AG

(CRSP)

2023 8-K

Financial Results Announced

Funding Announcement

Fundraising Announcement

Financial Results Announced

Clinical Updates Released

Financial Results Release

Share Offering Planned

Financial Statements

Product Expansion

Elections and Re-elections

Financial Statements

Management Change

Financial Results

Financial Results

Financial Results Announcement

Approval of Amendment to CR...

Appointment of Julianne Bru...

Financial Results Announcement

Financial Results Announcement

Investment Agreement

Resignation of CMO

EMA Approval for CASGEVY

Amendment to Collaboration ...

FDA Approval and Milestone ...

Update on Immuno-Oncology P...

Financial Results Announcement

Resignation and Appointment

Financial Results Announcement

Amendment Approval

FDA Acceptance of BLAs for ...

Financial Results Announcement

FDA BLA Submission

Resignation of Director

License Agreement with Vert...

Appointment of New Chief Fi...

Financial Results Announcement

External Links:

CRISPR Therapeutics AG announced an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates, with preliminary data suggesting improved clinical profiles for next-generation candidates CTX112 and CTX131.

AI Assistant

CRISPR THERAPEUTICS AG

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.